Shanghai Henlius Biotech’s HLX11 (POHERDY®) Receives European Commission Approval for HER2-Positive Breast Cancer Treatment 12
Shanghai Henlius Biotech Announces EU Approval for HLX11 (PO...
Sign in to continue:
Shanghai Henlius Biotech Announces EU Approval for HLX11 (PO...
Easyhold Group Holdings Limited - EGM Poll Results and Share...
Abbisko Cayman Limited 2025 Annual Report – Key Highlights f...
Shanghai Conant Optical Co., Ltd. Annual Report 2025: Key Hi...
Key Highlights Completion of Acquisition: FAR Internati...
CSPC Pharmaceutical Group Limited 2025 Annual Results: Key H...
Scholar Education Group Announces Share Purchase Under Share...
Simcere Pharmaceutical Group Annual Report 2025: Key Highlig...
Fortior Technology (Shenzhen) Co., Ltd. 2025 Annual Results ...
Prinx Chengshan Holdings 2025 Annual Report: Investor Insigh...